On April 15, 2013, the Supreme Court will hear oral arguments in the Myriad Genetics v. Association for Molecular Pathology litigation. The patent world is watching, particularly those who focus on emerging technologies. On March 14, 2013, the NanoBusiness Commercialization Association filed a brief in support of Myriad Genetics (brief prepared by Foley & Lardner, LLP). In addition to arguing that the patent claims should be patent eligible, which is the essence of the case, the brief also argues that patents do not preempt others from experimenting on, improving upon, or designing around a patented invention. With today being the first day of the new first-to-file regime, patent lawyers of all stripes are busy these days keeping up with dramatic changes to the patent system. The Supreme Court could use the Myriad case to establish a new paradigm for patent eligibility. Stay tuned.
Related Insights
April 3, 2026
Energy Current
Texas Legislature Sets Its Sights on Data Centers and AI: What You Need to Know
Texas House and Senate leadership recently released their interim charges, which serve as "homework assignments" for legislative…
April 3, 2026
Foley Viewpoints
For Your Eyes Only? Not Quite: Shadow AI in the Workplace
While many companies are still developing governance frameworks for authorized AI tools, an emerging risk has quietly surfaced: employees using unauthorized transcription tools without the company’s or participants’ consent.
April 3, 2026
Manufacturing Industry Advisor
Connecticut Appellate Court Narrows Scope of Petroleum “Franchise” Protections for Gas Station Operators
The Appellate Court of Connecticut affirmed a trial court’s judgment in favor of a petroleum distributor/lessor, holding that convenience…